

AMENDMENTS TO THE CLAIMS

BT01 Rec'd PCT/PTC 09 FEB 2005

1. (Original) Use of xenon in the preparation of a medicament for providing analgesia in a newborn subject and/or a fetal subject.
2. (Original) Use according to claim 1 wherein the newborn subject is a mammal in the first four weeks after birth.
3. (Currently Amended) Use according to claim 1 ~~or claim 2~~ wherein the newborn or fetal subject is a human.
4. (Currently Amended) Use accordingly to ~~any preceding~~ claim 1 wherein the xenon is used in combination with pharmaceutically acceptable carrier, diluent or excipient.
5. (Currently Amended) Use according to ~~any preceding~~ claim 1 wherein the xenon is administered in combination with a sedative, an anaesthetic agent or a further analgesic agent.
6. (Currently Amended) Use according to ~~any preceding~~ claim 1 wherein the medicament is in gaseous form.
7. (Original) Use according to claim 6 wherein the medicament is in the form of a 20 to 70% v/v xenon/air mixture.
8. (Currently Amended) Use according to ~~any one of claims 1 to 5~~ claim 1 wherein the medicament is in liquid form.
9. (Original) Use according to claim 8 wherein the medicament is in the form of a lipid emulsion.
10. (Currently Amended) Use according to claim 8 ~~or claim 9~~ wherein the medicament is in a form suitable for intravenous, neuraxial or transdermal delivery.
11. (Original) A method of providing analgesia in a newborn subject, the method comprising administering to the subject a therapeutically effective amount of xenon.
12. (Original) A method of providing analgesia in a fetal subject, the method comprising administering to the mother of the fetal subject a therapeutically effective amount of xenon for both the mother and the fetal subject.
13. (Currently Amended) A method accordingly to claim 11 ~~or claim 12~~ wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

14. (Currently Amended) A method according to ~~any one of claims 41 to 43~~ claim 11 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

15. (Currently Amended) A method according to ~~any one of claims 41 to 43~~ claim 11 wherein the xenon is administered in the form of a lipid emulsion.

16. (Currently Amended) A method according to ~~any one of claims 41 to 43 or 45~~ claim 11 wherein the xenon is administered intravenously, neuraxially or transdermally.

17. (New) A method accordingly to claim 12 wherein the xenon is administered in combination with a pharmaceutically acceptable carrier, diluent or excipient.

18. (New) A method according to claim 12 wherein the xenon is administered in the form of a 20 to 70% v/v xenon/air mixture.

19. (New) A method according to claim 12 wherein the xenon is administered in the form of a lipid emulsion.

20. (New) A method according to claim 12 wherein the xenon is administered intravenously, neuraxially or transdermally.